Science: nanoparticle therapy for primary and metastatic breast cancer

Because of the non-specific binding of many nano carriers and targeted molecules with cell, extracellular and intravascular components, it is a great challenge to develop effective tumor cell targeted nano pharmaceutical preparations Recently, researchers from the University of Maryland School of medicine and other units have developed a therapeutic nanoparticles treatment platform, which can balance the receptor specific binding affinity on the cell surface, while maintaining the minimum interaction with blood and tumor tissue components (called "dart" nanoparticles), so as to improve blood circulation time, biological distribution and tumor cell specific uptake Photo source: Science Advanced According to the researchers, in the mouse model of primary three negative breast cancer and brain metastasis of breast cancer, the paclitaxel (PTX) - dart nanoparticles that can be directed to the cell surface receptor fibroblast growth factor-induced 14 (Fn14) are superior to the corresponding PTX nanoparticles without targeting group and the FDA approved PTX nanoparticle Abraxane These results provide new ideas for the effective development of therapeutic nanoparticles and evidence for the continued development of dart platform for primary and metastatic tumors reference material: